CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: MILR1 (ImmuneEditome ID:284021)

1. Gene summary of enriched editing regions for MILR1

check button Gene summary
Gene informationGene symbol

MILR1

Gene ID

284021

GeneSynonymsAllergin-1|C17orf60|MCA-32|MCA32
GeneCytomap

17q23.3

GeneTypeprotein-coding
GeneDescriptionallergin-1|allergy inhibitory receptor 1|mast cell antigen 32|probable mast cell antigen 32 homolog
GeneModificationdate20230517
UniprotIDQ7Z6M3;A0A087WVL4
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr17:64467675-64468612:+ENST00000605096.1ENSG00000271605.4MILR1UTR3AluSz,AluSx1,MLT1Dchr17:64467675-64468612:+.alignment
chr17:64467675-64468612:+ENST00000619286.3ENSG00000271605.4MILR1UTR3AluSz,AluSx1,MLT1Dchr17:64467675-64468612:+.alignment
chr17:64467675-64468612:+ENST00000620304.3ENSG00000271605.4MILR1UTR3AluSz,AluSx1,MLT1Dchr17:64467675-64468612:+.alignment


Top

2. Tumor-specific enriched editing regions for MILR1


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for MILR1


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr17:64467675-64468612:+GBMEERENSG00000164975,SNAPC30.28472.0516e-024.3807e-070.4023imageNEIF4A3;ELAVL1;FBL;FUS;IGF2BP2;MSI1;NOP56;U2AF2NAMacrophages_M0GSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr17:64467675-64468612:+DLBCEERENSG00000142634,EFHD2-0.63589.2349e-031.0306e-04-0.5310imageNEIF4A3;ELAVL1;FBL;FUS;IGF2BP2;MSI1;NOP56;U2AF2NAT_cells_gamma_deltaGSVA_HALLMARK_COMPLEMENT
chr17:64467675-64468612:+DLBCEERENSG00000111641,NOP20.61981.3189e-021.1438e-050.5873imageNEIF4A3;ELAVL1;FBL;FUS;IGF2BP2;NOP56;U2AF2NANK_cells_restingGSVA_HALLMARK_MYC_TARGETS_V2
chr17:64467675-64468612:+DLBCEERENSG00000188878,FBF1-0.57941.3697e-024.8013e-03-0.4004imageNEIF4A3;ELAVL1;FBL;FUS;IGF2BP2;MSI1;NOP56;U2AF2FBF1Macrophages_M2GSVA_HALLMARK_ANDROGEN_RESPONSE
chr17:64467675-64468612:+DLBCEERENSG00000186827,TNFRSF4-0.58281.8905e-024.6663e-03-0.4016imageNFBL;FUS;U2AF2TNFRSF4T_cells_regulatory_(Tregs)GSVA_HALLMARK_G2M_CHECKPOINT
chr17:64467675-64468612:+DLBCEERENSG00000147168,IL2RG-0.57822.1029e-029.3940e-04-0.4623imageNEIF4A3;IGF2BP2;U2AF2IL2RGT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V2
chr17:64467675-64468612:+DLBCEERENSG00000143179,UCK20.57172.5429e-025.2602e-060.6049imageNEIF4A3;ELAVL1;FBL;FUS;IGF2BP2;MSI1;NOP56;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V2
chr17:64467675-64468612:+DLBCEERENSG00000067221,STOML1-0.57062.7751e-026.1547e-04-0.4766imageNEIF4A3;ELAVL1;FBL;FUS;IGF2BP2;NOP56;U2AF2NAGSVA_HALLMARK_MITOTIC_SPINDLE
chr17:64467675-64468612:+DLBCEERENSG00000113356,POLR3G0.53214.1079e-026.2248e-040.4762imageNEIF4A3;ELAVL1;FBL;FUS;IGF2BP2;MSI1;NOP56;U2AF2POLR3GNK_cells_restingGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE
chr17:64467675-64468612:+DLBCEERENSG00000101417,PXMP4-0.53354.3233e-023.9743e-03-0.4082imageNEIF4A3;ELAVL1;FBL;FUS;IGF2BP2;MSI1;NOP56;U2AF2NAPlasma_cellsGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE
chr17:64467675-64468612:+GBMEERENSG00000164975,SNAPC30.28472.0516e-024.3807e-070.4023imageNEIF4A3;ELAVL1;FBL;FUS;IGF2BP2;MSI1;NOP56;U2AF2NAMacrophages_M0GSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr17:64467675-64468612:+DLBCEERENSG00000142634,EFHD2-0.63589.2349e-031.0306e-04-0.5310imageNEIF4A3;ELAVL1;FBL;FUS;IGF2BP2;MSI1;NOP56;U2AF2NAT_cells_gamma_deltaGSVA_HALLMARK_COMPLEMENT
chr17:64467675-64468612:+DLBCEERENSG00000111641,NOP20.61981.3189e-021.1438e-050.5873imageNEIF4A3;ELAVL1;FBL;FUS;IGF2BP2;NOP56;U2AF2NANK_cells_restingGSVA_HALLMARK_MYC_TARGETS_V2
chr17:64467675-64468612:+DLBCEERENSG00000188878,FBF1-0.57941.3697e-024.8013e-03-0.4004imageNEIF4A3;ELAVL1;FBL;FUS;IGF2BP2;MSI1;NOP56;U2AF2FBF1Macrophages_M2GSVA_HALLMARK_ANDROGEN_RESPONSE
chr17:64467675-64468612:+DLBCEERENSG00000186827,TNFRSF4-0.58281.8905e-024.6663e-03-0.4016imageNFBL;FUS;U2AF2TNFRSF4T_cells_regulatory_(Tregs)GSVA_HALLMARK_G2M_CHECKPOINT
chr17:64467675-64468612:+DLBCEERENSG00000147168,IL2RG-0.57822.1029e-029.3940e-04-0.4623imageNEIF4A3;IGF2BP2;U2AF2IL2RGT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V2
chr17:64467675-64468612:+DLBCEERENSG00000143179,UCK20.57172.5429e-025.2602e-060.6049imageNEIF4A3;ELAVL1;FBL;FUS;IGF2BP2;MSI1;NOP56;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V2
chr17:64467675-64468612:+DLBCEERENSG00000067221,STOML1-0.57062.7751e-026.1547e-04-0.4766imageNEIF4A3;ELAVL1;FBL;FUS;IGF2BP2;NOP56;U2AF2NAGSVA_HALLMARK_MITOTIC_SPINDLE
chr17:64467675-64468612:+DLBCEERENSG00000113356,POLR3G0.53214.1079e-026.2248e-040.4762imageNEIF4A3;ELAVL1;FBL;FUS;IGF2BP2;MSI1;NOP56;U2AF2POLR3GNK_cells_restingGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE
chr17:64467675-64468612:+DLBCEERENSG00000101417,PXMP4-0.53354.3233e-023.9743e-03-0.4082imageNEIF4A3;ELAVL1;FBL;FUS;IGF2BP2;MSI1;NOP56;U2AF2NAPlasma_cellsGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE
chr17:64467675-64468612:+GBMEERENSG00000164975,SNAPC30.28472.0516e-024.3807e-070.4023imageNEIF4A3;ELAVL1;FBL;FUS;IGF2BP2;MSI1;NOP56;U2AF2NAMacrophages_M0GSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr17:64467675-64468612:+DLBCEERENSG00000142634,EFHD2-0.63589.2349e-031.0306e-04-0.5310imageNEIF4A3;ELAVL1;FBL;FUS;IGF2BP2;MSI1;NOP56;U2AF2NAT_cells_gamma_deltaGSVA_HALLMARK_COMPLEMENT
chr17:64467675-64468612:+DLBCEERENSG00000111641,NOP20.61981.3189e-021.1438e-050.5873imageNEIF4A3;ELAVL1;FBL;FUS;IGF2BP2;NOP56;U2AF2NANK_cells_restingGSVA_HALLMARK_MYC_TARGETS_V2
chr17:64467675-64468612:+DLBCEERENSG00000188878,FBF1-0.57941.3697e-024.8013e-03-0.4004imageNEIF4A3;ELAVL1;FBL;FUS;IGF2BP2;MSI1;NOP56;U2AF2FBF1Macrophages_M2GSVA_HALLMARK_ANDROGEN_RESPONSE
chr17:64467675-64468612:+DLBCEERENSG00000186827,TNFRSF4-0.58281.8905e-024.6663e-03-0.4016imageNFBL;FUS;U2AF2TNFRSF4T_cells_regulatory_(Tregs)GSVA_HALLMARK_G2M_CHECKPOINT
chr17:64467675-64468612:+DLBCEERENSG00000147168,IL2RG-0.57822.1029e-029.3940e-04-0.4623imageNEIF4A3;IGF2BP2;U2AF2IL2RGT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V2
chr17:64467675-64468612:+DLBCEERENSG00000143179,UCK20.57172.5429e-025.2602e-060.6049imageNEIF4A3;ELAVL1;FBL;FUS;IGF2BP2;MSI1;NOP56;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V2
chr17:64467675-64468612:+DLBCEERENSG00000067221,STOML1-0.57062.7751e-026.1547e-04-0.4766imageNEIF4A3;ELAVL1;FBL;FUS;IGF2BP2;NOP56;U2AF2NAGSVA_HALLMARK_MITOTIC_SPINDLE
chr17:64467675-64468612:+DLBCEERENSG00000113356,POLR3G0.53214.1079e-026.2248e-040.4762imageNEIF4A3;ELAVL1;FBL;FUS;IGF2BP2;MSI1;NOP56;U2AF2POLR3GNK_cells_restingGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE
chr17:64467675-64468612:+DLBCEERENSG00000101417,PXMP4-0.53354.3233e-023.9743e-03-0.4082imageNEIF4A3;ELAVL1;FBL;FUS;IGF2BP2;MSI1;NOP56;U2AF2NAPlasma_cellsGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE

More results



Top

4. Enriched editing regions and immune related splicing for MILR1


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

5. Enriched editing regions and immune infiltration for MILR1


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000271605.4,MILR1ACCEAGT_cells_regulatory_(Tregs)4.0127e-02-0.4406image
chr17:64467675-64468612:+BLCAEERT_cells_CD4_memory_activated9.6907e-03-0.2059image
ENSG00000271605.4,MILR1BLCAEAGT_cells_CD4_memory_activated9.6907e-03-0.2059image
chr17:64467675-64468612:+BRCAEERT_cells_gamma_delta2.5953e-02-0.0860image
ENSG00000271605.4,MILR1BRCAEAGT_cells_gamma_delta2.5953e-02-0.0860image
ENSG00000271605.4,MILR1CESCEAGT_cells_follicular_helper1.9937e-04-0.3320image
chr17:64467675-64468612:+DLBCEERT_cells_CD4_memory_activated1.6189e-020.3454image
ENSG00000271605.4,MILR1DLBCEAGT_cells_CD4_memory_activated1.6189e-020.3454image
chr17:64467675-64468612:+ESCAEERNeutrophils2.6794e-020.2540image
ENSG00000271605.4,MILR1ESCAEAGNeutrophils2.6794e-020.2540image
chr17:64467675-64468612:+GBMEERMacrophages_M02.2158e-020.1886image
ENSG00000271605.4,MILR1GBMEAGMacrophages_M02.2158e-020.1886image
chr17:64467675-64468612:+KIRCEERMast_cells_resting3.2998e-030.1769image
ENSG00000271605.4,MILR1KIRCEAGMast_cells_resting3.2998e-030.1769image
chr17:64467675-64468612:+KIRPEERT_cells_regulatory_(Tregs)1.6781e-02-0.2004image
ENSG00000271605.4,MILR1KIRPEAGT_cells_regulatory_(Tregs)1.6781e-02-0.2004image
chr17:64467675-64468612:+LGGEERT_cells_CD4_naive1.3321e-020.1480image
ENSG00000271605.4,MILR1LGGEAGT_cells_CD4_naive1.3321e-020.1480image
chr17:64467675-64468612:+LIHCEERT_cells_CD4_memory_activated3.6648e-02-0.2270image
ENSG00000271605.4,MILR1LIHCEAGT_cells_CD4_memory_activated3.6648e-02-0.2270image
chr17:64467675-64468612:+LUADEERPlasma_cells1.2928e-020.1382image
ENSG00000271605.4,MILR1LUADEAGPlasma_cells1.2928e-020.1382image
chr17:64467675-64468612:+LUSCEERB_cells_memory1.2664e-02-0.1718image
ENSG00000271605.4,MILR1LUSCEAGB_cells_memory1.2664e-02-0.1718image
chr17:64467675-64468612:+OVEERNK_cells_activated8.3278e-030.1686image
ENSG00000271605.4,MILR1OVEAGNK_cells_activated8.3278e-030.1686image
chr17:64467675-64468612:+PAADEERNeutrophils2.5922e-03-0.2693image
ENSG00000271605.4,MILR1PAADEAGNeutrophils2.5922e-03-0.2693image
chr17:64467675-64468612:+SARCEERT_cells_CD4_memory_resting3.1308e-030.2273image
ENSG00000271605.4,MILR1SARCEAGT_cells_CD4_memory_resting3.1308e-030.2273image
chr17:64467675-64468612:+SKCMEERDendritic_cells_resting1.8604e-020.1434image
ENSG00000271605.4,MILR1SKCMEAGDendritic_cells_resting1.8604e-020.1434image
chr17:64467675-64468612:+STADEERMast_cells_resting7.2554e-03-0.1681image
ENSG00000271605.4,MILR1STADEAGMast_cells_resting7.2554e-03-0.1681image
ENSG00000271605.4,MILR1TGCTEAGT_cells_regulatory_(Tregs)4.1831e-03-0.3229image
chr17:64467675-64468612:+THCAEERMacrophages_M23.7842e-030.1600image
ENSG00000271605.4,MILR1THCAEAGMacrophages_M23.7842e-030.1600image
chr17:64467675-64468612:+THYMEERT_cells_CD4_naive4.4143e-020.2347image
ENSG00000271605.4,MILR1THYMEAGT_cells_CD4_naive4.4143e-020.2347image
chr17:64467675-64468612:+UCECEERMonocytes3.0449e-020.2797image
ENSG00000271605.4,MILR1UCECEAGMonocytes3.0449e-020.2797image
ENSG00000271605.4,MILR1UCSEAGMacrophages_M13.1775e-02-0.4695image


Top

6. Enriched editing regions and immune gene sets for MILR1


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr17:64467675-64468612:+BRCAEER5.2637e-05image1.0088e-02-0.0993image
ENSG00000271605.4,MILR1BRCAEAG5.2637e-05image1.0088e-02-0.0993image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr17:64467675-64468612:+BLCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER8.1909e-03-0.2103image
ENSG00000271605.4,MILR1BLCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG8.1909e-03-0.2103image
chr17:64467675-64468612:+BRCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER6.2184e-06-0.1736image
ENSG00000271605.4,MILR1BRCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG6.2184e-06-0.1736image
ENSG00000271605.4,MILR1CESCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.2507e-02-0.2264image
ENSG00000271605.4,MILR1DLBCGSVA_HALLMARK_MYC_TARGETS_V2EAG2.2121e-020.3297image
chr17:64467675-64468612:+DLBCGSVA_HALLMARK_MYC_TARGETS_V2EER2.2121e-020.3297image
chr17:64467675-64468612:+ESCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.3234e-02-0.2830image
ENSG00000271605.4,MILR1ESCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.3234e-02-0.2830image
ENSG00000271605.4,MILR1GBMGSVA_HALLMARK_G2M_CHECKPOINTEAG7.6451e-050.3203image
chr17:64467675-64468612:+GBMGSVA_HALLMARK_G2M_CHECKPOINTEER7.6451e-050.3203image
ENSG00000271605.4,MILR1HNSCGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG2.6407e-020.2080image
chr17:64467675-64468612:+KIRCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER9.3627e-06-0.2642image
ENSG00000271605.4,MILR1KIRCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG9.3627e-06-0.2642image
ENSG00000271605.4,MILR1KIRPGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG8.8674e-03-0.2189image
chr17:64467675-64468612:+KIRPGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER8.8674e-03-0.2189image
ENSG00000271605.4,MILR1LAMLGSVA_HALLMARK_ANGIOGENESISEAG4.2496e-02-0.2097image
chr17:64467675-64468612:+LAMLGSVA_HALLMARK_ANGIOGENESISEER4.2783e-02-0.2094image
ENSG00000271605.4,MILR1LGGGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG2.8619e-11-0.3846image
chr17:64467675-64468612:+LGGGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER2.8619e-11-0.3846image
chr17:64467675-64468612:+LIHCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.2268e-03-0.3274image
ENSG00000271605.4,MILR1LIHCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.2268e-03-0.3274image
ENSG00000271605.4,MILR1LUADGSVA_HALLMARK_SPERMATOGENESISEAG2.8606e-040.2006image
chr17:64467675-64468612:+LUADGSVA_HALLMARK_SPERMATOGENESISEER2.8606e-040.2006image
chr17:64467675-64468612:+LUSCGSVA_HALLMARK_BILE_ACID_METABOLISMEER3.1975e-02-0.1481image
ENSG00000271605.4,MILR1LUSCGSVA_HALLMARK_BILE_ACID_METABOLISMEAG3.1975e-02-0.1481image
ENSG00000271605.4,MILR1MESOGSVA_HALLMARK_APICAL_SURFACEEAG1.5696e-02-0.2781image
ENSG00000271605.4,MILR1OVGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.3166e-03-0.2045image
chr17:64467675-64468612:+OVGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.3166e-03-0.2045image
chr17:64467675-64468612:+PRADGSVA_HALLMARK_HEME_METABOLISMEER2.6423e-030.4331image
ENSG00000271605.4,MILR1PRADGSVA_HALLMARK_HEME_METABOLISMEAG2.6423e-030.4331image
chr17:64467675-64468612:+SARCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER8.3834e-07-0.3703image
ENSG00000271605.4,MILR1SARCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG8.3834e-07-0.3703image
ENSG00000271605.4,MILR1SKCMGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG8.5684e-06-0.2676image
chr17:64467675-64468612:+SKCMGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER8.5684e-06-0.2676image
ENSG00000271605.4,MILR1STADGSVA_HALLMARK_MYC_TARGETS_V2EAG2.8615e-060.2888image
chr17:64467675-64468612:+STADGSVA_HALLMARK_MYC_TARGETS_V2EER2.8615e-060.2888image
ENSG00000271605.4,MILR1TGCTGSVA_HALLMARK_MITOTIC_SPINDLEEAG5.4987e-040.3848image
ENSG00000271605.4,MILR1THCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG8.0148e-05-0.2167image
chr17:64467675-64468612:+THCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER8.0148e-05-0.2167image
ENSG00000271605.4,MILR1THYMGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG1.0308e-050.4880image
chr17:64467675-64468612:+THYMGSVA_HALLMARK_FATTY_ACID_METABOLISMEER1.0308e-050.4880image
chr17:64467675-64468612:+UCECGSVA_HALLMARK_PROTEIN_SECRETIONEER3.7238e-050.5060image
ENSG00000271605.4,MILR1UCECGSVA_HALLMARK_PROTEIN_SECRETIONEAG3.7238e-050.5060image
ENSG00000271605.4,MILR1UCSGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.0834e-04-0.7238image


Top

7. Enriched editing regions and drugs for MILR1


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000271605.4,MILR1ACCCGP.60474EAG2.2556e-030.6163image
chr17:64467675-64468612:+BLCAGDC.0449EER2.8854e-060.3635image
ENSG00000271605.4,MILR1BLCAGDC.0449EAG2.8854e-060.3635image
chr17:64467675-64468612:+BRCAAZD.2281EER7.2048e-090.2213image
ENSG00000271605.4,MILR1BRCAAZD.2281EAG7.2048e-090.2213image
ENSG00000271605.4,MILR1CESCImatinibEAG2.3616e-03-0.2740image
ENSG00000271605.4,MILR1COADAKT.inhibitor.VIIIEAG7.2811e-030.5232image
ENSG00000271605.4,MILR1DLBCCGP.60474EAG1.4842e-030.4461image
chr17:64467675-64468612:+DLBCCGP.60474EER1.4842e-030.4461image
ENSG00000271605.4,MILR1ESCABX.795EAG3.8733e-030.3276image
chr17:64467675-64468612:+ESCABX.795EER3.8733e-030.3276image
chr17:64467675-64468612:+GBMBIBW2992EER4.1389e-050.3314image
ENSG00000271605.4,MILR1GBMBIBW2992EAG4.1389e-050.3314image
ENSG00000271605.4,MILR1HNSCAZD7762EAG7.8676e-030.2478image
chr17:64467675-64468612:+KIRCCGP.60474EER2.5825e-050.2512image
ENSG00000271605.4,MILR1KIRCCGP.60474EAG2.5825e-050.2512image
chr17:64467675-64468612:+KIRPAZD7762EER1.8207e-030.2595image
ENSG00000271605.4,MILR1KIRPAZD7762EAG1.8207e-030.2595image
ENSG00000271605.4,MILR1LGGAZ628EAG1.4833e-050.2561image
chr17:64467675-64468612:+LGGAZ628EER1.4833e-050.2561image
chr17:64467675-64468612:+LIHCIPA.3EER2.1872e-030.3298image
ENSG00000271605.4,MILR1LIHCIPA.3EAG2.1872e-030.3298image
chr17:64467675-64468612:+LUADBexaroteneEER8.8809e-040.1841image
ENSG00000271605.4,MILR1LUADBexaroteneEAG8.8809e-040.1841image
ENSG00000271605.4,MILR1LUSCLapatinibEAG9.5023e-03-0.1790image
chr17:64467675-64468612:+LUSCLapatinibEER9.5023e-03-0.1790image
ENSG00000271605.4,MILR1MESOCGP.082996EAG1.2299e-020.2878image
ENSG00000271605.4,MILR1OVFH535EAG4.8255e-03-0.1799image
chr17:64467675-64468612:+OVFH535EER4.8255e-03-0.1799image
ENSG00000271605.4,MILR1PAADAZD.0530EAG3.8239e-04-0.3217image
chr17:64467675-64468612:+PAADAZD.0530EER3.8239e-04-0.3217image
chr17:64467675-64468612:+SARCBortezomibEER6.4914e-050.3040image
ENSG00000271605.4,MILR1SARCBortezomibEAG6.4914e-050.3040image
ENSG00000271605.4,MILR1SKCMFH535EAG1.3939e-07-0.3144image
chr17:64467675-64468612:+SKCMFH535EER1.3939e-07-0.3144image
ENSG00000271605.4,MILR1STADGDC0941EAG1.5203e-050.2678image
chr17:64467675-64468612:+STADGDC0941EER1.5203e-050.2678image
ENSG00000271605.4,MILR1TGCTCI.1040EAG2.1137e-030.3451image
chr17:64467675-64468612:+THCACI.1040EER6.1646e-080.2943image
ENSG00000271605.4,MILR1THCACI.1040EAG6.1646e-080.2943image
ENSG00000271605.4,MILR1THYMBI.D1870EAG1.5237e-02-0.2812image
chr17:64467675-64468612:+THYMBI.D1870EER1.5237e-02-0.2812image
chr17:64467675-64468612:+UCECGW843682XEER2.4617e-040.4565image
ENSG00000271605.4,MILR1UCECGW843682XEAG2.4617e-040.4565image
ENSG00000271605.4,MILR1UCSBortezomibEAG1.6192e-020.5178image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType